-
Professor LanPing Xu: Hematopoietic Stem Cell Transplantation for the Treatment of Severe Aplastic Anemia | 2024 CSCO Hematology Academic Conference
From January 26 to 28, 2024, the “Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee Work Meeting and 2024 CSCO Blood, Lymphoma, and Myeloma Diseases Academic Conference” was held in Haikou. Many authoritative hematologists from home and abroad gathered to share their insights. Professor LanPing Xu from the Hematology…
-
Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology
Lymphoma is one of the fastest-growing malignant tumors worldwide, and the incidence rate in China has been gradually increasing in recent years, posing a serious threat to the health of the population. From January 26 to 28, 2024, the “Work Conference of the Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee of the Chinese Society…
-
Professor Shuye Wang: Emphasizing early diagnosis and treatment of systemic amyloidosis to improve patient cure rates | 2024 CSCO Hematology Academic
Due to its low incidence and diverse clinical manifestations, patients with AL amyloidosis are often misdiagnosed or underdiagnosed, resulting in insufficient treatment. From January 26th to 28th, 2024, the “China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma…
-
Professor Yang Liang:Research Progress and Reflections on BTK Inhibitors in the Treatment of CLL Patients | 2024 CSCO Hematology Academic Conference
In recent years, with the emergence of new targeted drugs such as ibrutinib and zanubrutinib, the treatment strategies for chronic lymphocytic leukemia (CLL) patients have been changing, sparking widespread discussions. At the recent 2024 CSCO Hematology Academic Conference, Professor Yang Liang from Sun Yat-sen University Cancer Center shared some thoughts on the classical international phase…
-
Gene Therapy Milestone: Elevated FIX Levels Achieved in Chinese Hemophilia B Patients
Hemophilia B (HB) is a rare but severe bleeding disorder characterized by deficient or defective Factor IX (FIX), leading to prolonged bleeding episodes and increased morbidity and mortality. Traditional treatments,…
-
ASCO-GU Interview | Dr. Xuefeng Qiu: Timely Testing and Treatment, Let mCRPC patients benefit more from PARPi precision treatment
Oncology Frontier: At this year’s conference, research and application of PARP inhibitors, particularly olaparib, in advanced prostate cancer have emerged as hot topics. Could you discuss the new data and…
-
Professor Kailin Xu : From Clinical to Scientific Questions—Entry Points for CAR-T Research | 2024 CSCO Hematology Conference
CAR-T cell therapy is currently a hot research topic in the field of hematology, but how to transform the clinical issues of CAR-T cell therapy into scientific research questions remains a challenge for many clinicians. From January 26th to 28th, 2024, the “Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory…
-
Prof. Jun Ma: Key Components for Hematologic Malignancies’ Future – Medical Administration, Pharmaceuticals, and Doctor-Patient Relations | 2024 CSCO
Amidst the waves and scenic beauty, from January 26th to 28th, the “China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference” was grandly held in the beautiful city of Haikou. Renowned experts and scholars from…
Connecting Medical Expertise through Media